Medical instruments
HOME > BUSINESS > Medical instruments

Shandong Saikesaisi Biological Technology Co., Ltd.

Shandong Saikesaisi Biotechnology Co., Ltd. is located in the Biomedical Industrial Park in the High-tech Zone of Jinan City. The company was established in 2003 with a registered capital of 200 million yuan and covers an area of 30,000 square meters. Currently has 400 million yuan in fixed assets, more than 600 employees. The company has a strong and innovative R&D team, with more than 100 R&D personnel including postdoctoral, doctoral, and graduate students. The company has more than 30 national invention patents and is a national high-tech enterprise specializing in R&D, production, sales and service of polymer and biomaterial implanted medical device products.

The company is aiming at the frontier areas of the world, keeping pace with the development of high-end medical devices at home and abroad, relying on two innovative platforms: "Shandong Province In vivo Implantable Materials Engineering and Technology Research Center" and "Shandong Enterprise Technology Center". The company is currently researching and developing and has launched domestically. There are more than 50 high-tech products with leading international standards. The products currently on the market mainly include state-of-the-art new products, Septim®; the second in the world after Arista, the first domestic starch hemostatic product instantane®; the second domestically-listed non-adhesive liquid following ONYX. Embolization material Xavier®; CFDA approved China’s first entry into innovative medical devices for special approval of “green channel” Sai Ning® and more.

In recent years, in order to meet the needs of market development, the company has continued to explore new marketing and management models. Chairman Mr. Zou Fangming proposed the “M520” plan in 2012, which means that 20 millionaires will be created in 5 years. By leaning on talents in policy and funding, we encourage outstanding sales people to establish their own subsidiaries. At present, 23 branches have been established throughout the country and the business covers 30 provinces, cities and autonomous regions across the country. The social influence of enterprises and product brands has been gradually expanded and the market competitiveness has been continuously enhanced.

In order to meet market demand and expand production capacity, the company started the construction of a new factory area in 2015. The new plant site is located on the west side of Dazheng Road in the High-tech Zone, on the south side of the Biomedical Park, covering an area of 140 acres and a total construction area of 76,000 square meters. The total investment of the project is 640 million yuan. The main contents of the project are medical device GMP standard workshop, medical equipment warehouse, raw material warehouse, pilot plant and related supporting facilities.

After the project is completed, a brand-new, modern, and large-scale production capacity Saikesaisi will be standing proudly in the Jinan Pharmaceutical Valley Industrial Park, leading the Yaogu medical device industry, fully bearing the company's new projects currently in the R&D phase and being in clinical practice. The new products in the research stage will be put into production to benefit the majority of patients and provide the public with more abundant products and services.


Shandong Saikesaisi Biotechnology Co., Ltd. is willing to create and manufacture high-quality medical products with a rigorous scientific attitude, providing safe, high-quality services for the majority of patients, medical workers, and the entire industry. We are committed to building our company into a 100-year-old national brand that enjoys a good reputation. We actively promote products and services to the world and become leaders in the industry.

Product display


The Septim® surgical anti-blocking liquid is the company’s first medical device product developed and put into the market. It was developed in cooperation with the School of Life Sciences of Shandong University and was approved by the CFDA in 2007. As one of the country’s largest production bases for sterile carboxymethyl chitosan raw materials and preparations, Septim® has a clinical use volume of over 1 million cases and a sales volume of over 100 million. This product ranks first in the field of surgical anti-adhesion.

In 2008, Septim® was identified as "National Key New Product". As an industry model, it was invited by the China National Institute of Food and Drug Control 2 times to participate in the formulation of national standards for chitosan products in 2010 and 2015 respectively.


Instantaneous Microporous Hemostatic Powder is another star product of Cytec Biotech. It is the only haemostatic material combining plant starch and carboxymethyl chitosan. It is also the world's second starch after Arista. Hemostatic products. The annual clinical use in China exceeds 300,000 cases and sales exceeds 100 million yuan. The product consists of a starch polysaccharide and carboxymethyl chitosan emulsified cross-linked and copolymerized. It has a microporous structure and can be used for hemostasis in various traumatic hemorrhage areas such as heart surgery and neurosurgery. It is the first patented product in China.

Instantaneous® is a pioneering application of plant starch to the field of hemostasis. The R&D team found that potato starch has very good adhesion and water absorption characteristics. After encountering blood, it can quickly absorb the water in the blood and quickly form a gel to achieve hemostasis. At the same time, carboxymethyl chitosan as an excellent hemostatic anti-adhesive material can increase the gel strength, inhibit bacteria and promote wound healing. The product was approved by CFDA in the category of medical device registration in 2012, and in the same year it was awarded the "Shandong Provincial Department of Science and Technology's Independent Achievement Transformation Major Project".


The EVAL® non-adhesive liquid embolization agent is the second interventional embolization product for endovascular embolization treatment of cerebrovascular malformations that has been launched globally after ONYX products in the United States. It obtained national invention patents in 2009 and was approved by CFDA in 2012. It is the first non-adhesive liquid embolic agent listed in China, and is the only domestic brand to date.

The product is a suspension composed of ethylene-vinyl alcohol copolymer (EVAL), DMSO (dimethyl sulfoxide), anhydrous ethanol and hydrazine materials in a certain ratio. When it comes in contact with an aqueous solution (such as blood), DMSO quickly diffuses into the aqueous solution. EVAL precipitates as a solid and embolizes. This helps aneurysmal malformation patients to heal cerebrovascular malformations by interventional therapy, greatly reducing The risk of treatment through craniotomy, and reduce the burden on the patient.

Sai Naoning:

Sai NaoNing® absorbable dura mater sealant is the first neurosurgical specialty product of Cycers Biotech Co., Ltd. after 10 years of R&D investment, acting on the human dura mater, and assisting in sealing the dura to prevent leakage of cerebrospinal fluid. . The product was patented in 2017. It is the world's first three-component mixed-durable dura mater-sealed medical gel, and it is also the first domestically marketed product. At the same time, Sai Na Ning® is the first batch of Class III medical devices approved by the CFDA to enter the special “green channel” for innovative medical device approval.

Bi Jing:

Bijing® nasal allergen barrier ointment is the first generic product of Alergol Pollen Blocker developed exclusively by Dr. Theiss Natural Products in Germany. It is mainly used to prevent allergies caused by inhalant allergens such as pollen, dust, aphids, and animal skins. Rhinitis and asthma. By forming a protective film in the nasal cavity, inhaled allergens are effectively blocked. At the same time, because the product does not contain any hormone component, it does not have any stimulation on the contact site and is highly favored by allergic patients. CFDA was approved in 2010 and national invention patents were obtained in 2012.


Runbao® Double Dose Dry Moisturizing Solution is a first medical device for relieving dry mouth symptoms in China that was developed by Seixia Biotechnology through the exploration of clinical needs. Prior to this, temporary dry mouth during perioperative period, and Radiotherapy leads to long-term dry mouth caused by damage to the salivary glands, and there are no symptomatic treatment products. The advent of Runbao® relieves the patient's dry mouth and various oral problems and solves the clinical needs of oral care. It acts as an “artificial saliva” to provide continuous lubrication and moisturization to the oral cavity. The product was approved by CFDA in 2013 and obtained national invention patent in the same year.

Ya Jing:

The inspiration for the development of Yajing® Draining Cream was based on the fact that the gum line caused permanent damage to the gums when the gums were dislocated. The patient had to endure gum pain and bleeding. In order to avoid the pain of patients, Yajing® uses a new row of spasm technology to push out the gums with the aid of the cream, and the ingredients of the cream can effectively stop the bleeding. In 2011, it was the first domestic medical device product for drainage and was approved by CFDA.


Aierqing® Hydrogel Eye Mask is a professional corneal protection product used to prevent exposure keratitis caused by incomplete eyelid closure due to general anesthesia, deep coma, paralysis of facial nerves, and more. At present, it is mainly used in general anesthesia patients and patients in ICU wards to create an eye moist environment through eye patch dressing and reduce the incidence of keratitis. Since the launch of the product, eye problems have been relieved for millions of patients, and the product won a national invention patent in 2017.


Zhuchuangsu® is a further hemostatic product developed by Cysecs after Instantaneous®, mainly for traumatic bleeding in armaments and first aid. The product stimulates the endogenous coagulation mechanism by absorbing the moisture in the blood, and at the same time creates a stable and effective "golden ten minute" rescue window for the wounded by compressing the hemostasis to provide the doctor with sufficient follow-up wound treatment time. This product won national invention patent in 2013.